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Introduction: According to genome wide association (GWA) studies as well as candidate gene approaches,
Behçet’s disease (BD) is associated with human leukocyte antigen (HLA)-A and HLA-B gene regions. The HLA-B51
has been consistently associated with the disease, but the role of other HLA class I molecules remains controversial.
Recently, variants in non-HLA genes have also been associated with BD. The aims of this study were to further
investigate the influence of the HLA region in BD and to explore the relationship with non-HLA genes recently
described to be associated in other populations.
Methods: This study included 304 BD patients and 313 ethnically matched controls. HLA-A and HLA-B low
resolution typing was carried out by PCR-SSOP Luminex. Eleven tag single nucleotide polymorphisms (SNPs)
located outside of the HLA-region, previously described associated with the disease in GWA studies and having a
minor allele frequency in Caucasians greater than 0.15 were genotyped using TaqMan assays. Phenotypic and
genotypic frequencies were estimated by direct counting and distributions were compared using the χ2 test.
Results: In addition to HLA-B*51, HLA-B*57 was found as a risk factor in BD, whereas, B*35 was found to be
protective. Other HLA-A and B specificities were suggestive of association with the disease as risk (A*02 and A*24)
or protective factors (A*03 and B*58). Regarding the non-HLA genes, the three SNPs located in IL23R and one of
the SNPs in IL10 were found to be significantly associated with susceptibility to BD in our population.
Conclusion: Different HLA specificities are associated with Behçet’s disease in addition to B*51. Other non-HLA
genes, such as IL23R and IL-10, play a role in the susceptibility to the disease.Introduction
Behçet’s disease (BD) is a systemic vasculitis characterized
mainly by recurrent oral and genital ulceration, although
other clinical manifestations, such as skin lesions, ocular,
gastrointestinal and neurological disorders, are relatively
common [1]. The aetiology of BD remains unclear; never-
theless, imbalances in the innate or adaptive immune
response triggered by infectious agents or environmental
factors in genetically predisposed individuals could
be some of the underlying mechanisms of the disease.* Correspondence: mariaf.gonzalez.sspa@juntadeandalucia.es
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distribution, and reproduction in any mediumEvidence of genetic contributions to the pathogenesis of
the disease are based on familial aggregation, predomin-
ance in patients with Mediterranean or Asian ancestry and
association with the human leukocyte antigen (HLA) B51
(HLA-B51) region in several ethnic groups. Multiple stud-
ies investigating associations between HLA and BD have
been reported [2,3]. All of them described an association
between the disease and the specificity HLA-B51 inde-
pendent of the ethnicity of the study population [4]. Never-
theless, associations of this pathology with other HLA-B
allele groups are less consistent [5-12]. This lack of replica-
tion may be due to the lack or weaker association of BD
with other HLA-B allele groups, as well as with the rela-
tively small sample size included in each study, whichentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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derrepresented allele groups. The typing procedures have
evolved to achieve a better resolution. Nevertheless, the
basis of the association of HLA with BD remains elusive.
Very recently, in a study employing dense genotyping in
the HLA region, three peaks of association with the disease
were found: one of these single-nucleotide polymorphisms
(SNPs) is located in the HLA-A region, another is located
in the HLA-B human major histocompatibility complex
class I chain-related gene A (HLA-B-MICA) region and
another is located in the HLA-C region. After inferring
the classical HLA alleles from the SNPs, the authors of
that suggested that the robust association between HLA-B
*51 and BD is explained by a variant located between the
HLA-B and MICA genes [13]. Improved knowledge of the
HLA-B molecules associated with BD would help to estab-
lish the basis of this association. Contribution of the HLA
region has been estimated to represent approximately 20%
of the genetic component of this disease [14]. Different
studies designed to establish the contribution of other
HLA and non-HLA genes have been published. Two dif-
ferent approaches have been used in genetic association
studies and in BD. First, the candidate gene strategy has
permitted the establishment of the association of BD with
HLA-B51 and with other HLA and non-HLA genes [15].
Second, the free hypothesis approach has also been used
to assess the genetic component of BD [16-20]. Three of
these studies, which were carried out using a large-scale
SNP genotyping strategy (genomewide association studies
(GWASs)), were recently published [18-20]. In general,
these studies confirmed the association with HLA-B, iden-
tified a second HLA class I region independently associ-
ated with the disease in the HLA-A region and described
an association with other non-HLA regions [19,20]. The
two aims of the present study were to further investigate
the influence of the HLA region in BD and to explore the
relationship with the previously described non-HLA
genes associated with BD.
Methods
A total of 304 BD patients (134 males and 170 females)
with a mean age at onset ± SD of 38.7 ± 13.8 years fulfilled
the 1990 International Study Group classification criteria
for BD [21] and they were recruited into the study. A total
of 313 bone marrow and blood donors (50% males) were
included in the study as normal healthy controls. All the
participants were Spanish Europeans recruited from differ-
ent Spanish hospitals. The study was approved by all local
ethical committees of the corresponding hospitals, and all
the study participants gave their written informed consent
to participate. Clinical features of the patient group were
as follows: 100% had oral ulcers; 74.4% had genital ulcers;
49.8% had uveitis; 47.4% had arthritis; and 24.5% had vas-
cular involvement, 18.1% had neurological involvementand 19.1% had gastrointestinal. The distribution of the fre-
quencies of the different markers in the cohorts from dif-
ferent hospitals was not significantly different.
Peripheral blood was obtained from the healthy controls,
and peripheral blood or saliva served as the starting mater-
ial obtained from patients. Samples were obtained from
participants after they provided their written informed
consent. Genomic DNA was extracted using the QIAamp
DNA Mini Kit (Qiagen, Barcelona, Spain) according to the
manufacturer’s recommendations and stored at −20°C.
The purity of DNA was determined using a NanoDrop
spectrophotometer (Thermo Fisher Scientific, Wilmington,
DE, USA). Only DNA samples having a 260 nm to 280 nm
absorbance ratio between 1.7 and 2.0 and a final concen-
tration of 10 to 20 ng/μl were considered appropriate. Ten
DNA samples from saliva were eliminated because they
did not meet these quality criteria.
HLA-A and HLA-B low-resolution typing was carried
out by using the polymerase chain reaction sequence-
specific oligonucleotide (PCR-SSOP) Luminex method
using LABType SSO (One Lambda Inc., Canoga Park, CA,
USA) according to the manufacturer’s instructions. Briefly,
target DNA was PCR-amplified using HLA-A or HLA-B
group-specific primers. The biotinylated PCR products
were denatured and hybridized with specific probes bound
to color-coded microspheres. Phycoerythrin-conjugated
streptavidin was used to label and reveal reactions, and a
flow analyser, LABScan 100 (One Lambda Inc), was used
to identify fluorescence intensity in each microsphere. The
software HLA Fusion 2.0 (One Lambda Inc) was used to
assign the HLA typing of each locus. Typing of locus A
and locus B was possible for 92% and 93%, respectively, of
the DNA samples meeting the quality criteria.
Additionally, an intergene (LOC100129342) and six gene
regions (IL23R, IL10, CPVL, TDRD7/C9orf174, UBASH3B
and UBAC2) previously reported to be associated with BD
in GWASs in candidate gene studies were included
[18-20,22]. The SNPs were selected from among those in-
cluded in previous publications, taking into account the
minor allele frequency (MAF) in the Utah residents with
Northern and Western European ancestry from the
Centre d’Etude du Polymorphisme Humain collection
(CEU) population [23]. Only SNPs with MAF greater than
0.15 in the CEU were included in this study, one each for
LOC100129342 (rs11206377), CPVL (rs317711), TDRD7
(rs2061634), UBASH3B (rs4936742) and UBAC2
(rs7999348) and three for each of the two non-HLA loci
with the highest evidence of association with BD in
different populations, which are IL23R (rs17375018,
rs7517847 and rs1343151) and IL10 (rs3024498,
rs2222202 and rs1800872). Genotyping of these SNPs
was performed using the TaqMan SNP Genotyping
Assay (Applied Biosystems, Barcelona, Spain) and the
LightCycler 480 System (Roche, Barcelona, Spain).
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direct counting, and distributions were compared using
the χ2 test. Odds ratios (ORs) and 95% confidence intervals
(95% CI) were calculated according to Woolf ’s method
using the StatCalc calculator with the EPI Info software
package (Centers for Disease Control and Prevention, At-
lanta, GA, USA). In the case of the HLA univariate analysis,
P-values ≤0.001 (0.05 divided by 48 which is the number of
groups is the number of HLA alleles found in our popula-
tion) were considered significant, whereas P-values be-
tween 0.01 and 0.001 were considered to be suggestive of
an association and P-values between 0.05 and 0.01 were
considered marginally associated. The adjusted ORs were
calculated after constructing a logistic regression model
categorizing all the individuals according to the presence
or absence of the HLA-A and HLA-B groups with P < 0.05
in the univariate analysis (Epi Info 2002). In the cases of
HLA risk factors, the analysis proposed by Svejgaard and
Ryder to detect the strongest HLA association was also
used. This analysis consisted of different two-tailed Fisher’s
exact tests performed in various 2 × 2 tables using the
GraphPad Software QuickCalcs tool (http://graphpad.com/
quickcalcs/contingency1.cfm; GraphPad Software, La Jolla,
CA, USA), starting with the basic data collected in a 2 × 4
table that included the four phenotypic combinations of
the two HLA factors under study [24]. The ORs were cal-
culated according to Haldane’s modification of Woolf ’s
method, and P-values of tests 1 through 4 were corrected
by a factor of 6 as these authors suggested.
Gene–gene interactions were evaluated using the non-
parametric multifactor dimensionality reduction (MDR)
method [25-27]. A tenfold cross-validation was used to es-
timate the balanced testing accuracy (TA) and cross-
validation consistency (CVC) of MDR models. Balanced
accuracy is (sensitivity + specificity)/2, where sensitivity is
true-positive/(true-positive + false-negative) and specificity
is true-negative/(false-positive + true-negative). The MDR
model with the highest TA and CVC values was selected
as the best model for studying from one to n loci. Statis-
tical significance was evaluated using a 10,000-fold permu-
tation test.
Results
Table 1 displays allele frequencies of the HLA-A and
HLA-B groups in Spanish BD patients and healthy con-
trols. The statistical power ranked from 8 to 40 for
detecting ORs ≥1.2. Distribution of the frequencies of
the 19 HLA-A alleles that were found in our population
had a statistically significant difference in patients and
controls (P = 0.005 in a 2 × 19 contingency table). Three
of the HLA-A alleles were suggestive of an association
with susceptibility to BD. Two of these HLA-A alleles
had a higher frequency in patients: A*02 (0.34 vs. 0.26,
P = 0.003, OR = 1.47, 95% CI = 1.14 to 1.91) and A*24(0.11 vs. 0.07, P = 0.01, OR = 1.70, 95% CI = 1.10 to 2.52).
One allele, HLA-A*03, had a lower frequency in patients
(0.06 vs. 0.11, P = 0.003, OR = 0.53, 95% CI = 0.34 to 0.83).
With respect to HLA-B alleles, distribution of the 29 HLA-
B specificities found in our population was statistically sig-
nificantly different in patients and controls (P < 10–5 in a
2 × 29 contingency table). In addition to the association
repeatedly described with B*51 (0.23 vs. 0.07, P < 10–7,
OR = 4.11, 95% CI = 2.79 to 6.06), two other HLA-B alleles
were associated with BD. One of them, B*57, had a higher
frequency among patients (0.06 vs. 0.02, P = 0.00008, OR =
3.70, 95% CI = 1.78 to 7.83), whereas the other, B*35, had a
lower frequency in patients (0.07 vs. 0.12, P = 0.0007,
OR = 0.49, 95% CI = 0.32 to 0.76). Moreover, HLA-B*58
was suggestive of an association as protective (0.002
vs. 0.02, P = 0.007, OR = 0.10, 95% CI = 0.0 to 0.71)
and HLA-B*18 (0.05 vs. 0.09, P = 0.02, OR = 0.58, 95%
CI = 0.35 to 0.95) and B*38 (0.02 vs. 0.04, P = 0.03,
OR = 0.48, 95% CI = 0.23 to 0.99) had a marginal asso-
ciation also as protective. We categorized all the indi-
viduals according to the presence or absence of HLA
with P < 0.05 in the univariate analysis and calculated
the adjusted ORs using a logistic regression model
(Table 2). According to this analysis, the ORs conferred
by HLA-A*24, B*35, B*51, B*57 and B*58 remained sig-
nificant and similar after adjustment.
To further clarify whether the association of the differ-
ent HLA risk factors detected in the univariate analysis
were independent of HLA-B*51, we performed the ana-
lysis proposed by Svejgaard and Ryder to detect the stron-
gest HLA association. Different two by four tables were
built with the phenotypic combinations of HLA-B*51 and
HLA-A*02, HLA-A*24 and HLA-B*57 (Table 3). In the
cases of HLA-A*24 and HLA-B*57 the ORs were greater
than 1 in both HLA-B*51 positive (test 1) and negative
(test 2) individuals, although only in the second case the
test reached statistical significance. Nevertheless, these
tests 1 and 2 were not significant for HLA-A*02. The
combined associations of HLA-A*24 and also of B*57 with
HLA-B*51 increased the individual risks, but this was not
the case of A*02 (test 3). Finally, the contribution of HLA-
A*24 and HLA-B*57 were similar to the contribution of
B*51 whereas the contribution of A*02 was significantly
different (test 4).
Next, we genotyped different genes described as associ-
ated with BD in different GWASs by selecting SNPs with
MAF greater than 0.15 in the CEU population. The geno-
typing success ratio was greater than 96%, and the study
population was found to be within the Hardy–Weinberg
equilibrium for all the polymorphisms analysed (P > 0.05).
The statistical power was 50% to 73% to detect an OR ≥1.3,
depending on the MAF of each SNP. According to the re-
sults of univariate analysis (Table 4), the three SNPs located
in IL23R and one of the SNPs within IL10 were associated
Table 1 Allelic frequencies of the HLA-A and HLA-B allele
groups in Behçet’s disease patients and healthy controlsa
Region BD patients Controls P OR (95% CI)
HLA-A 2n = 542 (%) 2n = 626 (%)
01 51 (0.09) 63 (0.10)
02 186 (0.34) 164 (0.26) 0.003 1.47 (1.14 to 1.91)
03 34 (0.06) 70 (0.11) 0.003 0.53 (0.34 to 0.83)
11 31 (0.06) 47 (0.08)
23 20 (0.04) 25 (0.04)
24 59 (0.11) 42 (0.07) 0.01 1.70 (1.10 to 2.62)
25 3 (0.005) 8 (0.01)
26 19 (0.03) 27 (0.04)
29 40 (0.07) 50 (0.08)
30 23 (0.04) 33 (0.05)
31 19 (0.03) 13 (0.02)
32 18 (0.03) 22 (0.03)
33 11 (0.02) 20 (0.03)
34 2 (0.004) 0 (0.0)
36 1 (0.002) 0 (0.0)
66 7 (0.01) 5 (0.008)
68 16 (0.03) 32 (0.05)
69 1 (0.002) 4 (0.006)
80 1 (0.002) 1 (0.002)
HLA-B 2n = 548 (%) 2n = 626 (%)
07 34 (0.06) 40 (0.06)
08 25 (0.05) 25 (0.04)
13 5 (0.009) 5 (0.008)
14 35 (0.06) 57 (0.09)
15 35 (0.06) 24 (0.04)
18 29 (0.05) 55 (0.09) 0.02 0.58 (0.35 to 0.95)
27 16 (0.03) 19 (0.03)
35 36 (0.07) 78 (0.12) 0.0007 0.49 (0.32 to 0.76)
37 3 (0.005) 3 (0.004)
38 12 (0.02) 28 (0.04) 0.03 0.48 (0.23 to 0.99)
39 5 (0.009) 10 (0.02)
40 14 (0.02) 22 (0.03)
41 5 (0.009) 7 (0.01)
42 1 (0.002) 0 (0.0)
44 70 (0.13) 88 (0.14)
45 8 (0.01) 16 (0.03)
46 1 (0.002) 0 (0.0)
47 1 (0.002) 1 (0.002)
48 0 (0.0) 2 (0.003)
49 17 (0.03) 35 (0.06)
50 13 (0.02) 20 (0.03)
51 125 (0.23) 42 (0.07) <10–7 4.11 (2.79 to 6.06)
Table 1 Allelic frequencies of the HLA-A and HLA-B allele
groups in Behçet’s disease patients and healthy controlsa
(Continued)
52 5 (0.009) 8 (0.01)
53 8 (0.01) 14 (0.02)
54 0 (0.0) 1 (0.002)
55 6 (0.01) 3 (0.005)
56 4 (0.007) 1 (0.002)
57 34 (0.06) 11 (0.02) 0.00008 3.70 (1.78 to 7.83)
58 1 (0.002) 11 (0.02) 0.007 0.10 ( 0.0 to 0.71)
aBD, Behçet’s disease; CI, confidence interval; OR, odds ratio; HLA, human
leukocyte antigen. An allelic model was used. Allelic frequencies, calculated as
the number of each specific allele divided by the total number of alleles
(number of individuals × 2 (2n)), are shown within parentheses. Only those
P-values ≤0.05 are indicated. P-values ≤0.001 were considered statistically
significant, and the corresponding HLAs were considered to be associated.
HLAs with P-values between 0.001 and 0.01 were considered suggestive of
association, and those with P-values between 0.01 and 0.05 were considered
marginally associated. The rest of the HLA specificities described (A*43, A*74,
B*59, B67, B*73, B*78, B*81 and B*83) were not detected in our population.
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model for all the combinations from one to six attributes
using the MDR system, including in the model all those
HLA and non-HLA attributes suggestive of or associated
with the disease as risk factors (B*51, B*57, A*02, A*24,
rs17375018 and rs2222202). The best one-locus model, as
expected, was HLA-B*51 (TA = 0.6556, CVC = 10/10;
Pc < 0.0001), and the best two-attribute model was HLA-B
*51+HLA-B*57, which had the highest TA (TA = 0.6845,
CVC = 10/10; Pc < 0.0001).
Discussion
The first finding of the present work is the confirmation
of a second HLA-B allele group as a risk factor for BD, at
least in European populations. Thus, in addition to B*51,
we confirmed association of B*57 with BD in a model of
logistic regression analysis, an independent association
according to the analysis recommended by Svejgaard and
Ryder [24] and that the model B*51+B*57 performed theTable 2 Logistic regression analysisa
HLA P OR adjusted values (95% CI)
A*02 0.40 1.18 (0.80 to 1.72)
A*03 0.11 0.66 (0.38 to 1.11)
A*24 0.02 1.84 (1.11 to 3.04)
B*18 0.06 0.59 (0.35 to 1.02)
B*35 0.008 0.50 (0.30 to 0.84)
B*38 0.20 0.61 (0.29 to 1.30)
B*51 <10–5 4.96 (3.21 to 7.66)
B*57 0.0002 4.16 (1.98 to 8.76)
B*58 0.04 0.11 (0.01 to 0.91)
aCI, confidence interval; HLA, human leukocyte antigen; OR, odds ratio. The
model included those HLA factors with P < 0.05 in the univariate analysis.
Table 3 Basic data and 2 × 2 comparisons to detect the
strongest human leukocyte antigen association of the
risk factorsa
A*02 B*51 BD patients Controls
+ + 72 29
+ – 76 112
– + 45 11
– – 73 161
A*24 B*51
+ + 26 6
+ – 36 30
– + 91 34
– – 119 237
B*57 B*51
+ + 8 0
+ – 24 11
– + 111 40
– – 131 262
Factor 1-B*51 A*02 A*24 B*57
Pc OR Pc OR Pc OR
Test 1 >0.05 0.62 >0.05 1.54 >0.05 6.17
Test 2 >0.05 1.49 0.008 2.38 <0.0006 4.25
Test 3 <0.0006 5.40 <0.0006 8.10 0.0012 33.9
Test 4 <0.0006 0.17 >0.05 0.45 >0.05 0.77
aBD, Behçet’s disease; HLA, human leukocyte antigen; odds ratio; Pc, corrected
value of P. Test 1: ++ vs. –+ was performed to determine whether the HLA
proposed factor was associated in B*51 positives. Test 2: +− vs. –– was
designed to determine whether the HLA proposed factor was associated in
B*51 negatives. Test 3: ++ vs. –– was conducted to determine the combined
association between the HLA proposed factor and HLA-B*51. Test 4: +− vs. –+
was done to determine whether the associations between the HLA proposed
factor and HLA-B*51 were different. Pc was calculated from the different 2 × 2
tables using Fisher’s exact test and corrected by multiplying by 6 (see [23]).
Each comparison included B*51 and other HLA risk factors associated with the
disease or suggestive of an association with the disease.
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cluding HLA and non-HLA factors associated with the
disease, Consistent with one previous study describing the
same association in a UK cohort, the OR for B*57 was
similar to that for B*51 in our study population [7]. More-
over, HLA-B*35 was detected as protective in our cohort.
This HLA-B allele group had previously been found to be
protective in an Italian cohort with a very limited sample
size [28]. Interestingly, our study suggests a protective ef-
fect of B*58 because its frequency is significantly decreased
among patients before correction and remains associated
in the logistic regression analysis. Although this result
needs confirmation, it is in agreement with different re-
ports where a slight decrease in the frequency of HLA-B
*58 was observed [6,8,28]. Both B57 and B58 have lower
worldwide frequencies than B51 and B35; therefore, the
statistical power to detect associations with the same ORs
is worse. Noticeably, the only patient bearing B*58 had alsoB*51. HLA-B51 and B57 have the Bw4 epitope which is
the ligand of the natural killer (NK) cell inhibitory receptor
KIR3DL1. Interactions between Bw4 and KIR3DL1 have
been proposed as a possible underlying mechanism to ex-
plain the relationship between HLA-B and BD. However, a
large number of common HLA-B alleles encoding mole-
cules with the Bw4 epitope (for example, B*44, B*49) have
never been associated with BD. In this regard, B*35, pro-
tective according to our results, encodes molecules without
the Bw4 epitope, but B*58 (which our study suggests is
protective) encodes HLA molecules with this epitope. It
has been described that changes at specific positions of the
HLA-B molecule affect the interaction of Bw4 with
KIR3DL1 [29]. Among them, position 97 (α2 domain) is
very interesting because most of the HLA-B alleles with
the Bw4 epitope (including B*58) encode proteins with
97R or 97S. The only exceptions are proteins encoded by
alleles of the groups HLA-B*13, HLA-B*27, HLA-B*51,
HLA-B*52 and HLA-B*57 [30]. From among these groups,
B*51 and B*57 have been associated with BD, and HLA-B
*27 was not found to be associated with the disease in our
cohort. However, HLA-B*27 has been associated with BD
in other studies [8,10]. The remaining groups (B*13 and
B*52) have not been consistently associated with BD.
HLA-B*51 and HLA-B*52 differ in only two amino acid
positions, one of which is position 67 (α1 domain) (F67S).
Changes in position 67 also affect the interaction of
Bw4 with KIR3DL1 [29]. The amino acid in position 67
is shared between B*52 and B*13 [30]. Therefore, a pos-
sible explanation for the association of HLA-B and BD
is that these molecules have, in addition to the Bw4 epi-
tope, amino acid changes in specific positions such as
67 and 97, which modify interactions with KIR3DL1.
Thus, determining which of the HLA-B alleles are in-
volved in the disease could contribute to clarification in
the etiology of BD.
The HLA-A region has been associated with the disease
in GWASs, as well as in candidate gene studies, but it is
not clear whether it is the primary associated locus. The
distribution of the HLA-A groups was different in our pa-
tient and control cohorts. Nevertheless, in the univariate
analysis, none of the differences reach the significance level
necessary to be considered as associated, although three of
them were suggestive of an association, two as risk factors
and one as a protective factor. Moreover, HLA-A*24 was
independently associated according to the logistic regres-
sion analysis and the analysis recommended by Svejgaard
and Ryder [24]. Our results, as well as the previously
published GWASs, suggest that the weight of the HLA-A
region in the susceptibility to BD is weaker than that of
the HLA-B region. Relatively few studies have investigated
the influence of the HLA-A polymorphism in BD, and the
associations described have not been consistent. HLA-A
*26 has been described as associated with BD in Asian
Table 4 One-locus analysis of the non–human leukocyte antigen genes included in this studya
SNPs Location BD patients Controls P OR (95% CI)
LOC100129342
rs11206377 Chr1:39821691
A 280 (0.48) 279 (0.45)
G 306 (0.52) 347 (0.55) >0.05
IL23R
rs17375018 Chr1: 67427735
A 149 (0.26) 197 (0.32)
G 431 (0.74) 415 (0.68) 0.01 1.37 (1.06-1.78)
rs7517847 Chr1:67454257
G 189 (0.33) 272 (0.43)
T 391 (0.67) 354 (0.57) 0.0001 1.59 (1.25-2.02)
rs1343151 Chr1:67491717
A 192 (0.33) 250 (0.40)
G 390 (0.67) 374 (0.60) 0.01 1.36 (1.07-1.73)
IL10
rs3024498 Chr1: 205008152
C 89 (0.15) 115 (0.18)
T 495 (0.85) 507 (0.82) >0.05
rs2222202 Chr1:205012004
A 200 (0.34) 254 (0.41)
G 388 (0.66) 366 (0.59) 0.01 1.35 (1.06-1.71)
rs1800872 Chr1:205013030
A 172 (0.30) 157 (0.25)
C 408 (0.70) 463 (0.75) >0.05
CPVL
rs317711 Chr7:29068833
C 143 (0.25) 164 (0.27)
G 429 (0.75) 454 (0.73) >0.05
TDRD7
rs2061634 Chr9:99145603
C 453 (0.79) 468 (0.75)
G 123 (0.21) 154 (0.25) >0.05
UBASH3B
rs4936742 Chr11:12214629
C 302 (0.54) 327 (0.53)
T 258 (0.46) 291 (0.47) >0.05
UBAC2
rs7999348 Chr13:98730923
A 407 (0.71) 430 (0.70)
G 169 (0.29) 182 (0.30) >0.05
aBD, Behçet’s disease; CI, confidence interval; OR, odds ratio; Pc, conditional probability; SNP, single-nucleotide polymorphism. An allelic model was used. Allelic
frequencies are the number of each specific allele divided by the total number of alleles (number of individuals × 2) are shown within the parentheses.
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http://arthritis-research.com/content/15/5/R145populations [5,16], but only one study in a Greek European
population with a very limited number of patients reported
an association with HLA-A26 [31]. We did not detect dif-
ferences in the distribution of A*26 between patients and
controls. Interestingly, A*24, a suggested risk factor in our
work, is one of the few HLA-A specificities with the Bw4
epitope. Taking our data and those reported in other stud-
ies to date, we think that, contrary to the situation with
HLA-B, a worldwide association of HLA-A with BD is un-
likely to be found. Additionally, it is not completely clear
whether other genes located near the HLA-A locus, such
as HLA-E (ligand of the NK receptor CD94:NKG2A) could
be primarily responsible for the association observed. In
this way, HLA-E is highly selective in binding peptides de-
rived from HLA class I leader sequences, and this condi-
tion regulates its expression on the cell surface [32]. Thus,
polymorphisms located in the leader sequence could influ-
ence the expression of HLA-E in the cell surface and, as a
consequence, the NK activity. Further studies are needed
to clarify which HLA-A allele groups are associated in
each ethnic group as well as the role of the HLA-A region
in BD.
Regarding the bases of the HLA association with BD, a
study in which three different peaks with independent ef-
fects were identified and replicated in the region was pub-
lished while our manuscript was under review. That study
also suggested that the association with the HLA-B*51
could be due to a noncoding variant located between
HLA-B and MICA [13]. The results of the study by
Hughes et al. are in agreement with the findings of other
previously reported studies [33]. Nevertheless, studies
designed to assess the association between MICA and BD
have had conflicting results, although most of them sup-
port the association of MICA being due to linkage disequi-
librium with HLA-B51. Moreover, different GWASs have
not found an independent association between MICA and
BD [16,19,20]. In the study by Hughes et al., HLA typing
was deduced by imputation from SNPs. Imputation is a
valuable tool for identifying and fine-mapping association
between one region and one disease, as well as to extract
much more information from existing GWAS data sets.
Nevertheless, the accuracy of the imputation is not 100%,
depending on the ethnicity of the population and the HLA
locus under study [34]. Therefore, it would be interesting
to compare these results where the HLA typing was
assigned by imputation with those obtained by HLA typing
to further clarify this question.
Regarding the non-HLA genes included in the study,
IL23R is the most strongly associated in our population
because the three SNPs within this region were associated
with BD, with ORs ranging from 1.36 to 1.59. One of the
SNPs located in IL10 was also significantly associated.
According to our sample size, we can detect associations
with ORs of about 1.3. The SNPs rs11206377 (intergene),rs3024498 (IL10), rs1800872 (IL10) and rs2061634 (TDR7)
had ORs between 1.1 and 1.3 in our cohort; therefore, our
study is underpowered in these cases. The rest of the SNPs
included do not seem to greatly influence susceptibility to
BD in our population, because they have ORs lower than
1.1. Specifically, rs799348, a functional SNP in UBAC2
which has been strongly associated with BD in the
Turkish population, has an OR of 1.0 in our population.
IL23R and IL10 genes have been found to be associated
to BD in GWASs as well as in candidate gene studies,
and this association has been replicated in other popu-
lations [19,20,22,35]. Polymorphisms in IL23R have
been associated with Crohn’s disease, rheumatoid arth-
ritis and ankylosing spondylitis, and variants of IL10
have been associated with ulcerative colitis and systemic
lupus erythematosus. Therefore, these genes could be in-
volved in a common pathway of susceptibility to several
autoimmune and autoinflammatory diseases [36-38].
Conclusion
Our study demonstrates an association of BD with B*57 in-
dependently of B*51, at least in European populations. Re-
garding HLA-A, taking our data together with those
reported to date, a worldwide association of HLA-A with
this disease is unlikely to be found. With respect to non-
HLA genes, IL-23R and IL10 played a role in this disease in
our population.
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